FemTech isn't "a niche" anymore — it's one of the fastest-growing pockets inside healthcare, with women's health startup investment hitting $2.6B in 2024 (up meaningfully vs. 2023) despite a tough fundraising market. (Silicon Valley Bank)

If you're building in fertility, maternal health, menopause, contraception, pelvic health, or women-specific diagnostics/devices/services, the fastest path to funding is not "pitch more VCs." It's "pitch the 5–15 investors who already believe."

When preparing your pitch to FemTech investors, having a professional data room is essential. Peony helps women's health startups organize investor materials with AI-powered document organization, track investor engagement with page-level analytics, and securely share sensitive clinical and financial data. With transparent pricing at $40/user/month, Peony delivers enterprise-grade secure data rooms without the $5,000-20,000 per-deal costs of legacy platforms.

Below is a curated list of five high-reputation, FemTech-aligned investors that are (a) meaningfully focused on women's health and (b) structurally set up to invest (not just "interested").

1) How to pick the right FemTech investors

Start with the 5 filters that matter most

1) Stage fit (and real check size). "Seed" can mean $250k or $5M. Match your round size to the investor's typical entry point (and whether they can follow). For example, AHA's Go Red fund explicitly targets Series A/B with defined deal sizing. (www.heart.org)

2) Your FemTech category + your "clinical burden." Investors split into:

Clinical-heavy (devices, diagnostics, therapeutics, regulated pathways)
Clinical-light (care delivery, digital health, consumer wellness)

Pick funds whose internal diligence muscle matches your risk profile.

3) Reimbursement & distribution reality. The fastest "yes" comes when you clearly answer: Who pays? Why now? How do you scale distribution? If you're B2B2C (employers, payers, health systems), show procurement + ROI. If DTC, show retention + LTV and tight CAC control.

4) Mission alignment without sounding ideological. Great FemTech investors care about equity and outcomes — but they still need a venture-return path. RH Capital is explicit that they are impact-first and venture-backed. (Rhia Ventures)

5) Proof type: outcomes, traction, or IP. Your "proof" should match your product:

Devices/diagnostics: clinical evidence + regulatory/reimbursement plan
Care delivery: cohort outcomes + unit economics
Consumer: retention, payback period, and credible differentiation

2) The 5 best FemTech investors to know in 2025

1) SteelSky Ventures

Why they're high-signal: SteelSky closed an inaugural fund with $72M AUM, positioning themselves as one of the largest VC platforms focused on women's healthcare, with a portfolio spanning maternal health, pelvic health, and care delivery innovation. (GlobeNewswire)

What they invest in: Women's healthcare across devices, consumer health, digital health, new care models, ePharmacy, and retail therapeutics. (American Hospital Association)

Stage: Early-stage venture (their fund announcement emphasizes building an ecosystem across women's health). (GlobeNewswire)

Notable portfolio examples (from their fund announcement): Cayaba Care, Origin, Twentyeight Health, Raydiant Oximetry, ConcertoCare (among others). (GlobeNewswire)

What wins them over: A crisp thesis on why women's health outcomes improve + why your go-to-market can actually scale (not just "big market"). If you're improving access for underserved populations, that's especially aligned with their positioning. (GlobeNewswire)

2) Portfolia

Why they're high-signal: Portfolia is one of the most consistently active platforms in women's health investing, with a multi-fund strategy and a large portfolio footprint. Their Women's Health Fund IV launched in August 2025 and builds on a 46-company women's health portfolio; they also cite 140+ investments and multiple unicorns/exits across their platform. (portfolia.co)

What they invest in: Broad women's health innovation across fertility, childbirth, menopause, oncology, cardiovascular health, mental health, longevity, and more. (portfolia.co)

Stage: Early to growth-stage (they explicitly describe investing from early through later stages depending on fund). (portfolia.co)

Signals that matter to them:

Clear wedge into a women-specific condition (or women-different/women-disproportionate condition)
Strong founding narrative + credible science/clinical plan
Distribution clarity (health systems/employers/payers vs DTC)

Founder-friendly angle: Their model is built around an active investor community; if you present well, you can convert champions fast. (portfolia.co)

3) RH Capital (Rhia Ventures fund)

Why they're high-signal: RH Capital is explicitly designed to back early-stage women's health with health equity at the core — which means they often "get it" when mainstream VCs still treat women's health like a corner case. (Rhia Ventures)

What they invest in: Across healthcare segments — diagnostics, devices, therapeutics, digital health, services, consumer health — with named focus areas like maternal health, contraception, fertility, menopause/midlife. (Rhia Ventures)

Stage: Early-stage venture. (Rhia Ventures)

What wins them over:

A strong equity/outcomes thesis that's measurable
Realistic access strategy (pricing, coverage, distribution)
Teams who understand the difference between "women's health" and "pink-washed wellness"

4) Avestria Ventures

Why they're high-signal: Avestria is a women's health + female-led life sciences specialist with clear diligence standards (clinical evidence, IP, regulatory/reimbursement thinking). NVCA describes them as investing Seed and Series A in women's health and female-led life science ventures. (NVCA)

What they invest in: Women's health and female-led life science ventures; they define women's health as conditions affecting women exclusively, differently, or disproportionately. (AVESTRIA VENTURES)

Stage: Typically Seed / Series A. (NVCA)

Evidence of ongoing platform activity: Their site shows Fund II closed July 2024 with a roster of investments (e.g., Axena Health, May Health, Meet Mae, Novocuff, and others listed). (AVESTRIA VENTURES)

What wins them over: If you have clinical validation plans, durable differentiation, and a believable reimbursement/regulatory path, you'll feel "understood" here (and they'll ask smart questions). (NVCA)

5) American Heart Association Ventures — Go Red for Women Venture Fund

Why they're high-signal: This is a category-defining strategic/mission-backed investor with a concrete mandate and clear check parameters — and founders often underrate how powerful that can be for credibility + clinical network access.

What they invest in: Evidence-based innovations improving women's cardiovascular and brain health via health services, digital health/IT, devices, and diagnostics — including solutions redesigned to better serve women's unique needs. (www.heart.org)

Stage + deal size: They come in at Series A and Series B (with selective seed) and state deal size up to $7M per company over multiple rounds. (www.heart.org)

What wins them over:

Clear linkage to women's cardio/brain outcomes (or adjacent risk factors)
Real-world evidence plan (studies, registries, measurable endpoints)
A product that can integrate into care pathways (not just "nice-to-have") (www.heart.org)

3) Five quick tips to pitch FemTech investors (and actually get to "yes")

Lead with the "why women" science, not the slogan. Show the clinical or biological reason your product must be women-specific (or women-different). Investors in this space reward rigor.
Make regulatory + reimbursement a slide, not a hand-wave. Even if you're pre-seed, outline: classification assumptions, pathway, timeline, cost range, and reimbursement strategy (or why you can scale without it).
Prove distribution early (one channel, one wedge). For employer/payer GTM: show a beachhead segment and ROI. For clinic GTM: show a repeatable workflow + champion-driven adoption. For DTC: show retention and payback — not downloads.
Treat privacy as part of product quality (especially in fertility). FemTech investors are hyper-aware that sensitive health data is existential risk; show your data posture clearly (minimize data, user control, compliance stance).
Ask for the right next step. Don't end with "thoughts?" End with one specific ask: intro to a strategic, a diligence call with their clinician advisor, or a partner meeting after you share a data room. Use a professional data room like Peony to organize clinical evidence, regulatory plans, and financials with AI-powered organization and track investor engagement with page-level analytics.

Why professional data rooms matter for FemTech fundraising

FemTech startups need to present complex documentation—clinical evidence, regulatory plans, financial projections, and validation data—professionally to build investor confidence.

Peony helps women's health startups create investor-ready data rooms with AI-powered organization that sets up in minutes instead of weeks.

Key benefits: page-level analytics show which documents investors review most, enterprise security protects sensitive health data, and transparent pricing at $40/user/month—93-99% cheaper than legacy platforms charging $5,000-20,000 per deal.

Conclusion

Raising capital from FemTech investors in 2025 requires matching your clinical burden, stage, and distribution model to the right funds. The investors on this list are actively deploying, but they're selective. Bring rigorous science, regulatory clarity, and a clean data room—not just mission.

Having a professional data room is table stakes for serious FemTech fundraising. Peony helps women's health startups organize investor materials, track engagement, and securely share sensitive clinical and financial data at a fraction of legacy platform costs.

Ready to pitch FemTech investors? Set up your investor data room with Peony in minutes, not weeks.

Q&A Section

What's the best way to organize investor materials for FemTech fundraising?

Peony offers AI-powered document organization that automatically structures clinical evidence, regulatory plans, financials, and validation data into a professional data room in minutes. Page-level analytics show which documents investors review most, helping you anticipate questions.

How can I track which FemTech investors are most engaged with my pitch?

Peony provides page-level analytics showing which documents investors review and how much time they spend on each section. This helps identify serious investors and tailor follow-up conversations with actionable insights.

What's the most cost-effective data room solution for FemTech startups raising capital?

Peony offers transparent pricing at $40/user/month—93-99% cheaper than legacy platforms charging $5,000-20,000 per deal. For a 5-person team, Peony costs $200/month vs $3,000-5,000+ for legacy platforms, delivering enterprise features at startup-friendly pricing.

How do I securely share sensitive clinical and financial information with FemTech investors?

Peony provides enterprise-grade security with identity-bound access, dynamic watermarking, and screenshot protection. With link expiry and instant access revocation, you maintain complete control over sensitive health data.

What data room features are essential for FemTech startups pitching to investors?

FemTech startups need data rooms that handle complex documentation: clinical evidence, regulatory plans, financials, and validation data. Peony offers AI-powered organization, page-level analytics, custom branding, and comprehensive security. With 10-minute setup vs weeks for legacy platforms, Peony helps FemTech startups look professional without breaking the budget.

Impress Investors

Top 5 FemTech Investors in 2025: The Founder's No-Fluff Guide to Raising in Women's Health